loratadine has been researched along with rupatadine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almansa, C; Balsa, D; Bartrolí, J; Carceller, E; Forn, J; García-Rafanell, J; Giral, M; Merlos, M | 1 |
| Morphy, R; Rankovic, Z | 1 |
| DeGraw, AJ; Distefano, MD; Keiser, MJ; Ochocki, JD; Shoichet, BK | 1 |
| Buschauer, A; Cuboni, S; Devigny, C; Eder, M; Hauger, B; Hausch, F; Höfner, G; Holsboer, F; Hoogeland, B; Pomplun, S; Strasser, A; Wanner, KT | 1 |
| Brazís, P; de Mora, F; Merlos, M; Puigdemont, A; Queralt, M | 1 |
| Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F | 1 |
| Camelo-Nunes, IC | 1 |
| Carbó, ML; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A | 1 |
| Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A | 1 |
| Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y | 1 |
| Srinivas, NR | 1 |
| Bennett, C; Carter, B; Cohen, SN; Sharma, M | 1 |
| Ding, L; Gu, P; Li, Q; Liu, B; Pan, L; Sun, C; Wu, C; Zhang, J | 1 |
| Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E | 1 |
| Antonijoan, R; Campo, C; Coimbra, J; García-Gea, C; Gich, I; Labeaga, L; Puntes, M; Valiente, R | 1 |
| Kannappan, V; Kanthiah, S | 1 |
| Bosma, R; Bushby, N; de Esch, IJ; de Graaf, C; Kooistra, AJ; Kuhne, S; Leurs, R; Sheppard, RJ; van den Bor, J; Vischer, HF; Wang, Z; Waring, MJ; Wijtmans, M | 1 |
3 review(s) available for loratadine and rupatadine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
New antihistamines: a critical view.
Topics: Anti-Allergic Agents; Blood-Brain Barrier; Central Nervous System Diseases; Cetirizine; Child; Cyproheptadine; Heart Diseases; Histamine H1 Antagonists, Non-Sedating; Humans; Hypersensitivity; Loratadine; Mast Cells; Piperazines; Receptors, Histamine H1; Terfenadine | 2006 |
H1-antihistamines for chronic spontaneous urticaria.
Topics: Cetirizine; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Loratadine; Randomized Controlled Trials as Topic; Urticaria | 2014 |
5 trial(s) available for loratadine and rupatadine
| Article | Year |
|---|---|
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Histamine H1 Antagonists; Humans; Loratadine; Male; Middle Aged; Platelet Activating Factor; Probability; Reference Values; Rhinitis, Allergic, Seasonal; Severity of Illness Index; Treatment Outcome | 2004 |
Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Cyproheptadine; Female; Food-Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; Male; Tablets | 2007 |
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Chromatography, High Pressure Liquid; Confidence Intervals; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Safety; Therapeutic Equivalency | 2008 |
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
Topics: Age Factors; Child; Child, Preschool; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Hungary; Loratadine; Male; Quality of Life; Remission Induction; South Africa; Time Factors; Treatment Outcome; Urticaria | 2016 |
Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers.
Topics: Adult; Benzimidazoles; Cross-Over Studies; Cyproheptadine; Double-Blind Method; Female; Healthy Volunteers; Histamine; Histamine Antagonists; Humans; Injections, Intradermal; Loratadine; Male; Piperidines; Skin | 2017 |
9 other study(ies) available for loratadine and rupatadine
| Article | Year |
|---|---|
[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Topics: Anaphylaxis; Animals; Benzocycloheptenes; Blood Pressure; Guinea Pigs; Histamine; Histamine H1 Antagonists; Ileum; In Vitro Techniques; Indicators and Reagents; Magnetic Resonance Spectroscopy; Male; Mice; Molecular Structure; Muscle Contraction; Muscle, Smooth; Piperidines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 1994 |
Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.
Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Green Fluorescent Proteins; Histamine H1 Antagonists, Non-Sedating; Ligands; Loratadine; Miconazole; Microscopy, Confocal; Molecular Structure; Pharmaceutical Preparations; Protein Interaction Mapping; Protein Prenylation; ras Proteins; Recombinant Fusion Proteins; Technology, Pharmaceutical | 2010 |
Loratadine and analogues: discovery and preliminary structure-activity relationship of inhibitors of the amino acid transporter B(0)AT2.
Topics: Amino Acid Transport Systems, Neutral; Binding, Competitive; Brain; Cell Membrane; Chemistry, Pharmaceutical; Electrophysiology; Green Fluorescent Proteins; HEK293 Cells; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Kinetics; Loratadine; Nerve Tissue Proteins; Patch-Clamp Techniques; Receptors, Histamine H1; Structure-Activity Relationship | 2014 |
In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1.
Topics: Animals; Antibodies; Calcimycin; Cell Line; Concanavalin A; Cyproheptadine; Dogs; Histamine Antagonists; Histamine Release; Humans; Immunoglobulin E; Loratadine; Mast Cells; Skin; Thiazoles; Tumor Necrosis Factor-alpha | 2000 |
Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Topics: Adult; Asian People; Calibration; Chromatography, Liquid; Cyproheptadine; Drug Stability; Female; Formates; Freezing; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Methanol; Molecular Structure; Platelet Activating Factor; Quality Control; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry; Time Factors; Water; Young Adult | 2009 |
Unsuspected polymorphic metabolism of rupatadine via its primary metabolite, desloratadine.
Topics: Cyproheptadine; Cytochrome P-450 CYP3A; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Mutation; Polymorphism, Single Nucleotide | 2009 |
Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study.
Topics: Chromatography, Liquid; Cyproheptadine; Female; Formates; Humans; Loratadine; Male; Plasma; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry | 2015 |
D-Optimal mixture design optimization of an HPLC method for simultaneous determination of commonly used antihistaminic parent molecules and their active metabolites in human serum and urine.
Topics: Anti-Allergic Agents; Chromatography, High Pressure Liquid; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Limit of Detection; Loratadine; Solid Phase Extraction; Terfenadine | 2017 |
Route to Prolonged Residence Time at the Histamine H
Topics: Cyproheptadine; Histamine H1 Antagonists; Humans; Kinetics; Loratadine; Molecular Docking Simulation; Protein Binding; Receptors, Histamine H1; Time Factors | 2019 |